Non-Small Cell Lung Cancer

EQRx's Lung Cancer Candidate Shows Improved Progression-Free Survival Versus Placebo
Merck, Athenex Join Forces To Evaluate Oraxol/Keytruda Combo In Lung Cancer
Bristol Myers' Neoadjuvant Opdivo/Chemo Therapy Yet To Reach Overall Survival Endpoint In Early-Stage Lung Cancer
Merck, Athenex Join Forces To Evaluate Oraxol/Keytruda Combo In Lung Cancer
Bristol Myers' Neoadjuvant Opdivo/Chemo Therapy Yet To Reach Overall Survival Endpoint In Early-Stage Lung Cancer
Lilly Presents Updated Data On Retevmo In Advanced RET Fusion-Positive Lung Cancer
Why Are Immutep Shares Trading Higher?

Non-Small Cell Lung Cancer Recent News

Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers
Junshi Biosciences - Coherus Toripalimab Chemo Combo Met Survival Endpoints In Lung Cancer Setting
BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC
Spectrum Pharma Highlights Poziotinib Data In Treatment-Naïve Lung Cancer Setting
Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) announced the presentation of 
FDA Approves Bristol Myers' Opdivo Plus Chemo In Neoadjuvant Lung Cancer Setting
The 
Mirati Therapeutics' Adagrasib Application Under FDA Review For Lung Cancer Setting
The 
Pfizer's Lorlatinib Scores European Approval In ALK-Positive Lung Cancer
The 
Amgen's Lumakras Approved In Japan For Pretreated Lung Cancer Patients
Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) has been approved in Japan for KRAS G12C-mutated positive, unres
EQRx's Sugemalimab Shows Significant Overall Survival Benefit In Lung Cancer Settings
EQRx Inc (NASDAQ: EQRX), along with its partner CStone Pharmaceuticals has announced data from Phase 3 GEMSTONE-302 trial of sugemalimab plus chemotherapy as a first-line treatment for stage IV non-small cell lung cancer (NSCLC).
Europe Approves Amgen's KRAS-Targeted Lung Cancer Therapy
The European Commission (EC) has 
Merck's Keytruda As Adjuvant Treatment Improves Disease-Free Survival In Lung Cancer Setting
Merck & Co Inc (NYSE: MRK) has announced that the Phase 3 KEYNOTE-091 trial, investigating Keytruda, 
Genprex's Lead Cancer Program Scores Second FDA Fast Track Tag For Lung Cancer Setting
The FDA has 
CytomX Posts Interim Data From Phase 2 Trial Of CD71-Targeting Cancer Candidate
CytomX Therapeutics Inc (NASDAQ: CTMX) 
Cullinan Oncology Posts Updated Data for CLN-081 in NSCLC EGFR Exon 20 Patients
Cullinan Oncology Inc (NASDAQ: CGEM) 
Janssen Secures Conditional EU Marketing Authorization For Rybrevant in Lung Cancer Setting
Johnson & Johnson’s (NYSE: JNJ) Janssen subsidiary has 
Roche Posts Encouraging Follow-up Data From Tiragolumab/Tecentriq Trial In Lung Cancer
Roche Holdings AG (OTC: RHHBY) reported 
Blueprint Medicines Expands Precision Therapy With Lengo Therapeutics Acquisition
Blueprint Medicines Corporation (NASDAQ: BPMC) has 
Roche's Gavreto Conditionally Approved In Europe For RET Fusion-Positive Lung Cancer
The European Commission (EC) has granted conditional marketing authorization to Roche
Iovance Shares Tumble After Cell Therapy Data From Lung Cancer Trial
Mirati Posts More Responses For Adagrasib-Keytruda Combo In Lung Cancer Setting
Bristol Myers' Opdivo Combo Meets Endpoint Goal In Lung Cancer Trial
Why Did Calithera Shares Dropped To 52-Week Low In Premarket Friday?
Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved